Clinical trials: Diseases of the Urinary System
Urinary Tract Infections
A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection
This is a non-randomized, open-label, one-treatment, one group study in participants with complicated urinary tract infection (cUTI) including pyelonephritis to characterize the pharmacokinetics of RO7079901 co-administered with…
- Trial name
- NCT03174795
- Testing
- RO7079901, Meropenem
- Where
- 14 sites in United States, Hungary and 3 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
This study assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease (ESRD) and cardiovascular deaths in patients with Stage 4 Chronic Kidney Disease (CKD) and type 2…
- Trial name
- BEACON (NCT01351675)
- Testing
- Bardoxolone Methyl: 20 mg
- Volunteers
- 2,185 people
- Sponsor
- Biogen
Multiple Myeloma
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in patients with "relapsed or refractory multiple myeloma" (hereinafter referred to as "relapsed or refractory MM") who have…
- Trial name
- NCT02922543
- Where
- Japan
- Volunteers
- 361 people
- Sponsor
- Celgene
Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT04152018
- Testing
- PF-06940434, PF-06801591
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 85 people
- Sponsor
- Pfizer
Hyperphosphatemia, End Stage Renal Disease
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
To evaluate the efficacy and safety of ferric citrate capsules for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing hemodialysis
- Conditions
- Hyperphosphatemia, End Stage Renal Disease, ESRD
- Trial name
- NCT03984760
- Testing
- Ferric Citrate, Sevelamer Carbonate
- Where
- 24 sites in China
- Volunteers
- 240 people
- Sponsor
- Panion & BF Biotech Inc.
Chronic Kidney Disease
Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
The purpose of the study is to evaluate the efficacy, safety and tolerability of balcinrenone/dapagliflozin compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria.
- Trial name
- MIRO-CKD (NCT06350123)
- Where
- 92 sites in United States, Austria and 13 more
- Volunteers
- 324 people
- Sponsor
- AstraZeneca
Hydronephrosis, Neurogenic Bladder
Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology
Primary objective was to determine efficacy of Alfuzosin in the treatment of children and adolescents 2-16 years of age with newly diagnosed or progressive hydronephrosis due to elevated detrusor Leak Point Pressure [LPP] of…
- Trial name
- Alfahydro (NCT00576823)
- Testing
- Alfuzosin
- Where
- 12 sites in Bulgaria, Canada and 10 more
- Volunteers
- 25 people
- Sponsor
- Sanofi
Diabetic Nephropathy
Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy
Nidufexor addresses fibrosis, oxidative stress, inflammation and cell death, and therefore has the potential to improve the management of diabetic kidney disease when added to the standard of care (SoC) (angiotensin converting…
- Trial name
- NCT03804879
- Testing
- Nidufexor, Standard of Care (SoC)
- Where
- 18 sites in United States, Argentina and 5 more
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Polycystic Kidney, Autosomal Recessive
A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
This study evaluates safety and tolerability of a single ascending dose of a tesevatinib liquid formulation administered to pediatric subjects with ARPKD.
- Trial name
- NCT03096080
- Testing
- Tesevatinib
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Kadmon Corporation, LLC
Carcinoma, Renal Cell, Carcinoma, Renal Cell (Advanced)
Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Renal cell carcinoma accounts for roughly 3 % of all cancer. It is a rather aggressive cancer type, which means that patients who present with an advanced disease have a rather poor prognosis.
- Trial name
- NCT00895674
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- 18 sites in Argentina, Austria and 16 more
- Volunteers
- 2,840 people
- Sponsor
- Bayer
Albuminuria
Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria
Albumin in the urine is usually a signal that you might be at risk of cardiovascular complications. The purpose of this study is to determine if the albumin in your urine can be decreased by the treatment regimen that consists of…
- Trial name
- NCT00095290
- Testing
- Ramipril + Irbesartan
- Where
- 92 sites in United States, Australia and 12 more
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic…
- Conditions
- Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell
- Trial name
- NCT02443324
- Testing
- Ramucirumab, Pembrolizumab
- Where
- 22 sites in United States, France and 4 more
- Volunteers
- 175 people
- Sponsor
- Eli Lilly and Company
Chronic Kidney Disease on Hemodialysis, Secondary Hyperparathyroidism
Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis
The purpose of this study was to investigate the initial dose and dose adjustment range for paricalcitol injection in patients with chronic kidney disease on hemodialysis who have secondary hyperparathyroidism.
- Trial name
- NCT00667576
- Testing
- Maxacalcitol, Paricalcitol
- Where
- 12 sites in Japan
- Volunteers
- 153 people
- Sponsor
- Abbott
Chronic Kidney Failure, Acute Kidney Failure
Theranova Randomized, Controlled, Trial (RCT) in China
Traditional hemodialysis (HD) therapy is very effective in clearing urea and smaller middle molecules, but is limited in clearing larger middle molecules.
- Trial name
- ROCKet (NCT05309291)
- Testing
- Theranova 400 Dialyzer, FX 800 Dialyzer
- Where
- 10 sites in China
- Volunteers
- 323 people
- Sponsor
- Vantive Health LLC
Benign Prostatic Hyperplasia (BPH), Overactive Bladder
A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.
To evaluate the influence of BR9006-1 and BR9006-2 on pharmacokinetics, safety, and tolerability when administered separately or co-administered to healthy male volunteers.
- Trial name
- NCT04485585
- Testing
- BR9006-1, BR9006-2
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Urinary Bladder Neoplasms
A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
The purpose of this study is to evaluate both the safety and tolerability of up to 4 dosing cycles of TAR-200 for 21 days per dosing cycle in the induction period.
- Trial name
- NCT03404791
- Testing
- TAR-200
- Where
- 12 sites in United States, Spain
- Volunteers
- 35 people
- Sponsor
- Janssen Research & Development, LLC
Renal Impairment, Heart Failure
A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011)
Part I is a 3-period, active comparator-controlled, fixed sequence study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-7145 compared to furosemide in participants with moderate-to-severe renal…
- Trial name
- NCT01558674
- Testing
- MK-7145, Furosemide, Torsemide
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Cell Carcinoma
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone or…
- Trial name
- NCT07195682
- Testing
- BMS-986506, Pumitamig, Ipilimumab
- Where
- 11 sites in United States, Canada and 3 more
- Volunteers
- 281 people
- Sponsor
- Bristol-Myers Squibb
Bladder Cancer
Clinical Evaluation of the miR Sentinel BCa™ Test to Diagnose Bladder Cancer in Hematuria Patients
The purpose of the study is to establish the clinical performance and utility of the miR Sentinel™ BCa Test, a urine exosome-based diagnostic test, as an aid in diagnosing bladder cancer.
- Trial name
- NCT04155359
- Where
- United States
- Volunteers
- 444 people
- Sponsor
- miR Scientific LLC
Carcinoma, Renal Cell
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Phase 1 study to investigate the tolerability and safety of lenvatinib in combination with Everolimus in participants with unresectable advanced or metastatic RCC.
- Trial name
- NCT02454478
- Testing
- Lenvatinib, Everolimus
- Where
- 3 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Eisai Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.